<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813481/bin/gr2.jpg"/> </div> <div class="text-side"> <h1>Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec.</h1> <p>A, Clitoral melanoma histology before initiation of talimogene laherparepvec treatment (hematoxylin-eosin stain; original magnifications: 100). B, Dermal fibrosis without viable melanocytic proliferation highlighting the treatment effect after 4 months of talimogene laherparepvec injections. (A and B, Hematoxylin-eosin stain; original magnifications: A, ×100; B, ×50.)</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36620496/" target="_blank">36620496</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>